









































































































Melanopsin-expressing	 retinal	 ganglion	 cells	 (mRGCs)	 constitute	 a	 system	 in	 the	15	
mammalian	 retina	 used	 for	 irradiance	 detection,	 regulating	 non-image	 forming	16	
functions,	such	as	photoentrainment	of	circadian	rhythms,	control	of	the	pupillary	light	17	
reflex,	masking	 response,	 light-regulated	melatonin	secretion,	and	modulation	of	 the	18	
sleep/wake	cycle.	There	are	five	subtypes	of	mRGCs	differentiated	by	morphology	and	19	
function.	 Recent	 years	 of	 research	 on	 mRGCs	 have	 identified	 a	 broad	 number	 of	20	
neurodegenerative	 diseases	 in	 the	 eye	 and	 the	 brain	 with	 altered	 physiologic	 light	21	
responses,	 leading	 to	 disturbances	 of	 non-image	 forming	 light	 response(s).	 In	 this	22	
review,	we	briefly	summarise	the	melanopsin	system	in	the	normal	retina	and	discuss	23	
its	role	in	connection	to	human	aging	(sleep/wake	problems)	and	retinal	pathology	in	24	
Alzheimer	 and	 Parkinson	 diseases,	 diabetic	 retinopathy,	 mitochondrial	 optic	25	
neuropathies,	glaucoma,	retinitis	pigmentosa,	and	in	photophobia	during	migraine	and	26	
































The	mammalian	eye	contains	a	 subset	of	 retinal	ganglion	cells	which	are	 intrinsically	2	
photosensitive	 due	 to	 the	 expression	 of	 the	 photopigment	melanopsin	 (OPN4).	 The	3	
melanopsin-expressing	retinal	ganglion	cells	(mRGCs),	which	show	maximum	sensitivity	4	
to	 the	 short-wavelength	 blue	 light,	 have	 been	 recently	 identified	 as	 a	 class	 of	5	
photoreceptors	that	mainly	support	non-image	forming	(NIF)	visual	functions	of	the	eye	6	
(Do	 and	Yau,	 2010).	 These	 include	photoentrainment	of	 circadian	 rhythms,	masking,	7	








al.,	 2000),	 and	 was	 elegantly	 demonstrated	 in	 a	 later	 study	 to	 render	 these	 cells	16	
intrinsically	photosensitive	(Berson	et	al.,	2002).	Subsequently,	melanopsin	cells	were	17	
detected	in	the	human	retina		(	Hannibal	et	al.,	2004;	Dacey	et	al.,	2005).		The	discovery	18	




Diseases	 involving	 the	neuroretina	may	affect	mRGCs	or	 input	pathways	and	 for	 this	23	
































































































demonstrated	 in	 both	 inner	 and	 outer	 retina	 projecting	 dendrites	 showing	 synaptic	8	
appositions	(Liao	et	al.,	2016)	with	bipolar	cells	expressing	the	synaptic	ribbon	marker	9	
Ctbp2	 (	 Jusuf	 et	 al.,	 2007;	 Grünert	 et	 al.,	 2011a;	 Hannibal	 et	 al.,	 2017).	 The	 Ctpb2-10	










The	 melanopsin-expressing	 RGCs	 constitute	 the	 neuronal	 monosynaptic	 pathway	 to	21	
retinal	target	areas	in	the	brain	involved	primarily	in	non-image	perception,	a	pathway	22	
known	as	 the	 retino-hypothalamic	 tract	 (RHT)	 (Hannibal	 and	 Fahrenkrug,	 2006).	 The	23	



































secretion	 and	 core	 body	 temperature	 are	 disrupted	 (Cajochen	 et	 al.,	 2006)	 with	3	
decreased	amplitude,	phase	advancement	and/or	altered	circadian	period	(	Myers	and	4	




structure,	altered	 light	perception	caused	by	 	a	 reduction	 in	 the	capacity	 to	 transmit	9	
short	 wavelength	 light	 due	 to	 a	 semicataractous	 lens	 is	 observed	 in	 aged	 people	10	












people	 over	 70	 years	 f	 age	 (	 La	 Morgia	 et	 al.,	 2010;	 Esquiva	 et	 al.,	 2017).	 These	23	
observations	 in	 the	 human	 retina	 correspond	 to	 observations	 that	 have	 also	 been	24	
described	in	rodents	(Semo	et	al.,	2003b).	Furthermore,	the	presence	of	lipofuscin	found	25	
in	melanopsin	cells	of	 increasing	age	could	 influence	their	functionality	 (Vugler	et	al.,	26	









































2004).	 Circadian	 rhythm	 dysfunctions	 are	 frequent	 in	 aging,	 but	 are	 even	 more	11	







decrease	 in	 RGCs	 is	 greatest	 in	 the	 central	 zone,	more	 specifically	 in	 the	 foveal	 and	19	
parafoveal	zone	of	the	retina	(Blanks	et	al.,	2012),	confirmed	by	OCT	studies	showing	a	20	





were	 specifically	 affected	 in	 AD,	 degenerating	 before	 visual	 bearing	 RGCs,	 even	 in	26	
younger	 patients	with	 a	 normal	 RGCs	 count	 (La	Morgia	 et	 al.,	 2016).	Moreover,	 AD	27	






































PD	 patients	 mainly	 suffer	 from	motor	 clinical	 features	 such	 as	 rigidity,	 tremor,	 and	10	
bradykinesia	(Fahn,	2006;	Postuma	et	al.,	2015;	Ferreira	and	Massano,	2017).	However,	11	
several	non-motor	symptoms	including	cognitive	decline	(Caballol	et	al.,	2007),	mood	12	
disturbance	 (Tan,	 2012),	 visual	 disruption	 (Archibald	 et	 al.,	 2009;	Weil	 et	 al.,	 2016),	13	












Dysfunction	of	 circadian	 rhythms	 in	PD	has	been	explained	 recently	among	different	26	
mechanisms	 by	 the	 occurrence	 of	 Lewy	 pathology	 in	 the	 SCN	 from	 PD	 patients	 (De	27	
Pablo-Fernández	et	al.,	2018).	However,	the	occurrence	of	retinal	pathology	involving	28	
mRGCs	 may	 also	 contribute	 to	 circadian	 disturbance.	 Two	 studies	 have	 recently	29	




























shown	 that	 mRGCs	 are	 lost	 in	 PD	 patients	 compared	 to	 control	 subjects	 and	2	
furthermore,	the	remaining	mRGCs	demonstrated	morphological	alterations	 (Ortuño-3	
Lizarán	et	al.,	2018).	As	retinal	mRGCs	are	responsible	for	light	entrainment	of	circadian	4	
rhythms	 and	 nocturnal	 melatonin	 secretion	 and	 are	 involved	 in	 mood	 and	 sleep	5	






of	preventable	blindness	 in	developed	countries	 (Congdon,	2003).	DR	 symptoms	can	12	
include	 floaters	 (dark	 spots),	 blurred	 vision,	 impaired	 colour	 vision,	 and	 vision	 loss	13	




(	 Fletcher	 et	 al.,	 2007a;	 Curtis	 et	 al.,	 2009).	 Despite	 its	 vascular	 nature,	 DR	 is	 also	 a	18	
neurodegenerative	disease	and	clinical	symptoms	often	occur	after	an	alteration	in	the	19	
retina	at	the	molecular,	cellular	and	functional	level	(Bearse	et	al.,	2004;	Fletcher	et	al.,	20	





















































injuries	 (	 Vugler	 et	 al.,	 2008;	 Cui	 et	 al.,	 2015).	 It	 has	 been	 suggested	 that	 factors	20	
contributing	to	the	resistance	of	mRGCs,	such	as	the	abundant	mitochondrial	population	21	




























































Retinitis	 pigmentosa	 (RP)	 is	 an	 inherited	 neurodegenerative	 retinal	 disease	26	
characterized	 by	 a	 progressive	 peripheral	 and	 night	 vision	 loss	 because	 of	 different	27	
mutations	in	the	rhodopsin	encoding	gene	leading	to	rod	degeneration	at	early	stages.	28	
This	rod	disturbance	leads	to	cone	impairments	with	a	consequent	central	vision	loss	in	29	



































severe	 degeneration	 in	 all	 layers	 of	 the	 retina	 and	 only	 few	mRGCs	were	 identified	9	
(Hannibal	et	al.,	2004).	In	a	rat	model	of	RP,	the	degeneration	of	mRGCs	was	relatively	10	







Migraine	 is	 a	 common	 episodic	 neurological	 dysfunction	 characterized	 by	 increased	18	






















































the	discovery	 of	mRGCs	 it	 has	 been	hypothesized	 that	 light	 transmitted	 via	 the	RHT	17	







































was	 affected	 in	 SAD	 patients	 (Roecklein	 et	 al.,	 2013).	 Interestingly,	 a	 study	 in	 non-1	
seasonal	major	depression	found	normal	PIPR	in	depressed	patients	similar	to	controls,	2	




Since	 the	 discovery	 of	 the	 melanopsin	 system	 in	 the	 mammalian	 eye,	 functional	7	
methods	 for	 evaluation	 of	 the	 NIF	 system	 is	 needed.	 Melanopsin-expressing	 RGCs	8	
located	 in	 the	 inner	 retina	demonstrate	a	high	sensitivity	 for	blue	 light	with	a	higher	9	
threshold	of	activation	compared	to	the	rods	and	cones	located	in	the	outer	retina.	Both	10	





the	 integrity	of	mRGCs	projections	 and	 the	 interaction	between	 the	outer	 and	 inner	16	
retinal	photoreception,	thereby	indicating	both	outer	retinal	function	of	rod	and	cone	17	








































regulation	 of	 non-image	 forming	 function,	 which	 can	 be	 present	 even	 in	 cases	 of	 severe	4	
blindness.	The	measurement	of	PLR,	which	is	already	being	used	in	some	diseases	such	as	age-5	
related	macular	degeneration	or	diabetic	retinopathy,	may	provide	information	on	the	state	of	6	



















































































































































































































































































































































































































































































































































































































































































































































































































M3,	 and	M4	 cells.	 Furthermore,	 gigantic	M1	 cells	 located	 in	 the	 ganglion	 cell	9	
layer	(GCL)	(GM1)	and	displaced	in	the	inner	nuclear	cell	layer	(INL)	(GDM1)	are	10	









Melanopsin	 immunoreactive	 retinal	 ganglion	 cells	 in	 a	 female	human	 retina	 (age	67)	20	
with	a	total	of	7046	mRGCs.	M2	and	M4	subtype	of	mRGCs	are	shown	in	red	dots,	other	21	
subtypes	(see	Fig.	1)	are	marked	by	green	dots.	Note	the	higher	density	of	M2/M4	cells	22	
in	the	nasal	part	of	the	retina.	23	
	24	
Fig.	3		25	
Melanopsin	immunoreactive	RGCs	in	the	human	retina	representing	an	area	with	high	26	
cell	density	(A)	of	the	perifoveal/foveal	retina	and	with	low	density	of	cells	(B)	from	the	27	
peripheral	retina.		28	
	29	
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